Skip to main content
SpringerLink
Log in

The Impact of Mean Platelet Volume (MPV) and JAK-2 Mutation on Thrombosis in Chronic Myeloproliferative Diseases

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Thrombosis and bleeding are the main complications of chronic myeloproliferative diseases. Mean platelet volume (MPV) is an important indicator of the platelet activation. The aim of the present study was to assess the interrelationships between MPV, JAK-2 gene mutation and thromboembolic events in patients with ET and PV. Patients with ET (n = 60) and PV (n = 46) were compared to the secondary erythrocytosis group (n = 19); and a control group of age and sex matched healthy volunteers (n = 52). Besides demographic, clinical and laboratory data; thrombotic and hemorrhagic events were recorded for each patient. Platelet counts, MPV and JAK2 mutations were studied; and their relation with thromboembolic events were investigated using SPSS program for statistical analysis. There was no significant difference between groups regarding age (p = 0.188). Mean platelet count was significantly higher in ET group than other groups (p < 0.0001). Mean platelet count in PV group was significantly higher than control (p < 0.0001) and secondary erythrocytosis groups (p < 0.0001). In the ET group, MPV values were significantly lower than the control group and PV group. In the ET group, those with thromboembolia had lower platelet counts. There was no relation between MPV and thromboembolic event rate in PV, ET and secondary erithrocytosis groups; while no event was recorded in the control group. There was no relation between thromboembolic event rate and JAK 2 mutation. The association of JAK-2 mutation and high MPV especially in ET and PV groups does not contribute to the thromboembolic events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tefferi A, Solberg LA, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141–149

    Article  CAS  PubMed  Google Scholar 

  2. Trowbridge EA, Martin JF (1987) The platelet volume distribution: a signature of the prethrombotic state in coronary heart disease. Thromb Haemost 58:714–717

    CAS  PubMed  Google Scholar 

  3. Thompson CB, Eaton KA, Princiotta SM et al (1982) Size dependent platelet subpopulations: relationship of platelet volume to ultra structure, enzymatic activity, and function. Br J Haematol 50:509–519

    Article  CAS  PubMed  Google Scholar 

  4. Bath PM, Missoouris CG, Buckenham T, Mac Gregor GA (1994) Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci (Lond) 87:253–257

    Article  CAS  Google Scholar 

  5. Beer PA, Green AR (2016) Essential thrombocythemia, 9th edn. In: Williams hematology. pp 1307–1318

  6. Bath P, Algert C, Chapman N, Neal B (2004) Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35:622–626

    Article  PubMed  Google Scholar 

  7. O’Malley T, Langhorne P, Elton RA, Steward C (1995) Platelet size in stroke patients. Stroke 26:995–999

    Article  PubMed  Google Scholar 

  8. Martin JF, Plumb J, Kilbely RS (1983) Changes in volume and density of platelet in myocardial infarction. Br Med J 287:456–459

    Article  CAS  Google Scholar 

  9. Erne P, Wardle J, Sanders K et al (1988) Mean platelet volume and size distribution and their sensitivity to agonist in patients with coronary artery disease and congestive heart failure. Thromb Haemost 59:259–263

    CAS  PubMed  Google Scholar 

  10. Martin J, Bath PMW, Burr ML (1991) Increased platelet size following myocardial infarction is associated with subsequent death and non-fatal reinfarction. Lancet 338:1409–1411

    Article  CAS  PubMed  Google Scholar 

  11. Pabon P, Nieto F, Morinigo J (1998) The effect of mean platelet volume on the short term prognosis of acute myocardial infarction. Rev Esp Cardiol 51:816–822

    Article  Google Scholar 

  12. Butterworth R, Bath P (1998) The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets 0:359–364

    Article  CAS  Google Scholar 

  13. Smyth DM, Martin JF, Michalis L (1993) Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest 23:361–367

    Article  CAS  PubMed  Google Scholar 

  14. Seneran H, İleri M, Altınbaş A et al (2001) Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 24:405–408

    Article  Google Scholar 

  15. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673–683

    Article  CAS  PubMed  Google Scholar 

  16. Mesa RA (2007) Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology 2007(1):355–362

    Article  Google Scholar 

  17. Baxter EJ, Scott LM, Campbell PJ et al (2005) Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 19–25(365):1054–1061

    Article  Google Scholar 

  18. Jeffery A, Thiele J, Raze A et al (2007) Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–1097

    Article  Google Scholar 

  19. Tefferi A (2007) JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 13:366–367

    Article  CAS  PubMed  Google Scholar 

  20. Tefferi A, Pardanani A (2007) Evaluation of increased hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc 82:599–604

    Article  CAS  PubMed  Google Scholar 

  21. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myelofibrosis. Cancer Cell 7:387–397

    Article  CAS  PubMed  Google Scholar 

  22. Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V 617 F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168

    Article  CAS  PubMed  Google Scholar 

  23. Tefferi A, Lasho TL, Schuager SM et al (2006) The clinical phenotype of wild type heterozygous and homozygous JAK2 V617F in polycythemia vera. Cancer 106:631–636

    Article  CAS  PubMed  Google Scholar 

  24. Vannuchi AM, Antoniolli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846

    Article  Google Scholar 

  25. Larsen TS, Pallisgaard N, Moler MB, Hasselbalch HC (2008) High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythemia: independence of the V617F allele burden. Hematology 13:71–76

    Article  PubMed  Google Scholar 

  26. Heler PG, Lev PR, Salim JP et al (2006) JAK2 V617F mutation in platelet from essential thrombocythemia patients: correlation with clinical features and analysis of STAT 5 phosphorylation status. Eur J Haematol 77:210–216

    Article  Google Scholar 

  27. Carabbio A, Finazzi G, Guerini V et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia interaction with treatment standard risk factors and JAK2 mutation status. Blood 109:2310–2313

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Haseki Training and Research Hospital, Millet Cd., Aksaray/Fatih, 34087, Istanbul, Turkey

    Mesut Ayer

  2. Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey

    İlhan Menken, Mehmet Yamak, Fatma Aylin Ayer & M. Burak Aktuğlu

  3. Department of Hematology, Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey

    Onur Kırkızlar

Authors
  1. Mesut Ayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. İlhan Menken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Yamak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatma Aylin Ayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Onur Kırkızlar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Burak Aktuğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mesut Ayer.

Ethics declarations

Conflict of Interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayer, M., Menken, İ., Yamak, M. et al. The Impact of Mean Platelet Volume (MPV) and JAK-2 Mutation on Thrombosis in Chronic Myeloproliferative Diseases. Indian J Hematol Blood Transfus 33, 181–187 (2017). https://doi.org/10.1007/s12288-016-0685-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-016-0685-8

Keywords

Search

Navigation